To date, several studies have explored alterations in the EGFR pathway in pancreatic cancer that are predictive factors for EGFR inhibition, such as EGFR mutations or amplifications and these reports have failed to document a meaningful prevalence of such alterations. This evidence concerns the gene EGFR and pancreatic neoplasm.